Cost-Effectiveness of Semaglutide for Secondary Prevention of Cardiovascular Disease in US Adults

Is semaglutide cost-effective in US adults with overweight or obesity and cardiovascular disease (CVD) but without diabetes?In this modeling-based economic evaluation of patients with overweight or obesity and CVD, lifetime treatment with semaglutide at 2023 prices had an incremental cost-effectiveness ratio of $148 100 per quality-adjusted life-year gained. An 18% price reduction to $7055 would make semaglutide therapy cost-effective at a threshold of $120 000 per quality-adjusted life-year gained.In this study, semaglutide for the secondary prevention of CVD was effective but meeting conventional cost-effectiveness thresholds will require additional price reductions.

Corresponding Author: Dhruv S. Kazi, MD, MSc, MS, Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center, 375 Longwood Ave, 4th Floor, Boston, MA 02215 (dkazi@bidmc.harvard.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.